Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3807236 | 0.83 | MAPT (0.38) | EGFRTSHRATMTDP1MAPT | |
| SCHEMBL2734464 | 0.80 | EGFR (0.58) | EGFRTSHRAKT1ATMMAPT | |
| SCHEMBL58239 | 0.78 | MAOA (0.47) | TSHRAKT1MAPTALDH1A1MAPK1 | |
| SCHEMBL9047896 | 0.71 | TSHR (0.43) | TSHRAKT1ATMMAPTALDH1A1 | |
| SCHEMBL50199 | 0.71 | CES1 (0.47) | TSHRAKT1ATMTDP1MAPT | |
| SCHEMBL7068869 | 0.70 | TSHR (0.41) | TSHRAKT1MAPTMAPK1HTT | |
| SCHEMBL54072 | 0.70 | KMT2A (0.56) | TSHRTDP1MAPTALDH1A1MAPK1 | |
| SCHEMBL436125 | 0.70 | TSHR (0.41) | TSHRAKT1ATMTDP1MAPT | |
| SCHEMBL29875319 | 0.70 | ALDH1A1 (0.41) | TSHRAKT1MAPTALDH1A1MAPK1 | |
| SCHEMBL8829796 | 0.69 | MAPT (0.46) | TSHRAKT1ATMTDP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268894-B2 | Compositions and methods for the treatment of infectious diseases | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-09-18 | — | — | US | disclosed |
| US-8202910-B2 | Compositions and methods for treatment of infectious disease | SEQUELLA, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-20110118307-A1 | Compositions and methods for the treatment of infectious diseases | GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2011-05-19 | — | — | US | disclosed |
| US-7842729-B2 | Anti tubercular drug: compositions and methods | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-11-30 | — | — | US | disclosed |
| US-20090192173-A1 | ANTI-TUBERCULAR DRUGS: COMPOSITIONS AND METHODS | SEQUELLA, INC. | 2009-07-30 | — | — | US | disclosed |
| US-7456222-B2 | Anti tubercular drug: compositions and methods | SEQUELLA, INC. (US) | 2008-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118307-A1 | Compositions and methods for the treatment of infectious diseases | TERT, C5, ELANE | EGFR 335/4885TSHR 2407/4885AKT1 4440/4885 |
| US-20090192173-A1 | ANTI-TUBERCULAR DRUGS: COMPOSITIONS AND METHODS | RIF1, TERT, ELL | EGFR 590/4885TSHR 2423/4885AKT1 4418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.